PDCD1 and small cell lung carcinoma: In contrast to our indirect comparison, Yang et al.’s retrospective cohort‐based meta‐analysis of ES‐SCLC patients treated with PD‐1 inhibitors as first‐line therapy revealed that longer PFS was observed in ES‐SCLC patients treated with PD‐1 inhibitors [12].